Biotech-Rakete mit... - 500 Beiträge pro Seite

[Meier M]

wahnsinns potentia, bis zum ATH! Servus zusammen, möchte nochmals zusätzlich einen
GLGC-thread anfangen. Meines erachtens ist der Wert zu unrecht runtergeprügelt worden,
auch wenn die Quartalszahlen nicht die erwünschten waren so sehe ich doch eine rosige
Zukunft für GLGC.

PROFIL:


Gene Logic Inc. is a leading provider of genomics information to the
global pharmaceutical, healthcare and life science industries. The
Company markets two types of gene expression database products:
custom databases and related software products, and the new
GeneExpressTM reference database suite, which the Company
believes to be the world’s most comprehensive survey of gene
expression in human and animal tissues. Since genes direct all biological
processes, gene expression information is increasingly recognized by
leading pharmaceutical companies as a fundamental tool for all aspects
of biomedical research, particularly drug discovery and development.

Since 1997, the Company has developed custom gene expression
databases for each of its customers’ internal programs and needs and
targeted to specific therapeutic areas of interest, including heart failure,
kidney disease, osteoporosis, psychiatric disorders and other major
illnesses. Building on this know-how, in March 1999 the Company
began developing the GeneExpress database suite of reference gene
expression information. The GeneExpress databases contain
information from a broad range of normal and diseased human tissues,
tissues from experimental animals, human and animal cell lines and
tissues that have been treated with many different drugs. The Company
completed development of the first commercial version of the
GeneExpress database suite in November 1999. The Company markets
GeneExpress through nonexclusive subscriptions to customers in the
pharmaceutical, biotechnology and diagnostic industries, and is
developing versions of the database suite to market to the academic
and government life science research community and to physicians and
patients. The first subscription to GeneExpress was sold in December
1999.

The Company generates the gene expression data in its laboratories
from tissues collected through the Company’s biorepository network
using two complementary technologiesthe GeneChip® microarrays
produced by Affymetrix Inc. and the Company’s own proprietary
READSTM gene expression technology. The combination of GeneChip
microarrays and READS enables the Company to obtain
comprehensive coverage of the genes expressed in virtually all
important tissue types. By the end of 1999, the GeneExpress database
contained gene expression profiles on over 1,000 tissue samples
representing more than 30 million gene expression data points. By the
end of 2003, the Company expects to have complete profiles on 30,000
tissue samples representing an estimated 3 billion gene expression data
points.

The Company has also developed sophisticated data management
software in conjunction with its database products to enable customers
to integrate the Company’s gene expression information with their own
in-house data, as well as with the gene sequence and other biological
information publicly available on the Internet. The Company’s software
includes powerful tools for the analysis of this information, allowing
users to conduct a broad variety of electronic experiments designed to
answer their specific questions about mechanisms of disease and drug
action.

The GeneExpress database suite can be used for many important
research applications, such as to discover and validate novel drug
targets, develop therapeutic compounds and facilitate clinical trials and
patient management. Because the gene expression information is
warehoused in electronic form in a relational database, the Company
has the flexibility to repackage the data into different versions for
customers requiring varying levels of information and pricing such
versions optimally. As a result, the Company can market the same
information to many different types of customers, thereby maximizing
the revenue potential of the underlying data. The Company believes its
GeneExpress database suite will become a fundamental reference
source of gene expression information for many scientists engaged in
industrial and academic biological research. Because the information is
distributed over the Internet, the Company believes it can also establish
a portal that will create multiple e-commerce promotional and
transactional revenue opportunities. These may include the promotion
and sale of third party products, such as custom gene chips, research
reagents and specialized genomic diagnostic products.

Customers for the Company`s custom databases, data management
software and GeneExpress database suite include:

AGY Therapeutics
Aventis (formerly Rhône-Poulenc Rorer Inc.
Aventis CropScience (formerly Hoechst Schering AgrEvo GmbH
Fujisawa Pharmaceuticals
Japan Tobacco
Merck & Co.
Organon (Akzo Nobel)
PE Biosystems
Procter & Gamble Pharmaceuticals
Schering-Plough Research Institute
SmithKline Beecham
Therapeutic Genomics
UCB Pharma
Wyeth-Ayerst Laboratories (American Home Products)

Products
Overview

The Company generates the gene expression data in its laboratories
from tissues collected through the Company’s biorepository network
using two complementary technologiesthe GeneChip® microarrays
produced by Affymetrix Inc. and the Company’s own proprietary
READSTM gene expression technology. The GeneChips currently
provide quantitative expression levels for 40,000 human genes for
which either full or partial sequences are known. The Company’s
READS technology does not depend on any prior knowledge of gene
sequence and is applicable to all animal types, and is extremely
sensitive. READS is used to determine the expression levels of novel
genes that are not represented on the GeneChip microarrays and genes
that are expressed at low abundance. The combination of GeneChip
microarrays and READS enables the Company to obtain
comprehensive coverage of the genes expressed in virtually all
important tissue types.

The GeneExpress Database Suite
The content of the GeneExpress database suite is organized into three
modules:

The BioExpress database allows subscribers to use gene expression
information to study normal physiology, elucidate the mechanisms of
disease, identify disease-associated pathways and select and prioritize
potential drug targets. This database represents a survey of gene
expression in a broad range of normal and diseased human tissues,
tissues from experimental animals and also human and animal cell lines.
The Company is also building more in-depth profiles of samples
specifically related to therapeutic areas in which the pharmaceutical
industry spends the majority of its research dollars. These include
central nervous system (or CNS), oncological and cardiovascular
disease, diabetes, osteoporosis and inflammatory and immunological
diseases.

The ToxExpress database contains gene expression profiles
produced by drugs and other compounds associated with known classes
of toxicity in the organs typically subject to such toxic effects like the
liver. These toxicity profiles can be used as references against which
new drug leads can be screened to assess their toxic potentials.
Screening early in the drug discovery and development process allows
researchers to potentially reject compounds having unacceptable
toxicity profiles before incurring the substantial expenses of traditional
animal toxicology studies and clinical trial failures. The database
currently contains gene expression data from liver tissue from
experimental animals treated in vivo at various dosages for varying time
periods and primary rat and human hepatocytes treated in vitro. During
the coming year, the Company intends to expand the database to
include toxicity profiles in CNS tissues, bone marrow, kidney and heart
tissue.

The PharmExpress database is analogous to the ToxExpress
database and contains gene expression profiles produced by a wide
range of marketed drugs across many human and animal tissue
samples. Subscribers can use this information to analyze mechanisms
of drug action at the molecular level, to re-engineer compounds to have
more specific effects and, potentially, to identify new indications for
existing products. The Company intends to expand the content of the
PharmExpress database in parallel with the number of tissue samples
accrued and processed. In the coming year, the Company will also
profile important categories of drugs in experimental animals in vivo and
in cellular systems in vitro at a range of dosages and treatment periods.

Custom Databases and Software Products

Gene Logic has been developing customized databases tailored to
specific customers’ internal programs and needs since 1997. The
Company has 13 customers for its custom gene expression and other
genomic databases and data management software. Eleven are major
pharmaceutical and life science technology companies, one a major
agricultural company and one a biotechnology company. Five of these
agreements provide the Company with various technology and database
access fees, research funding and up-front payments. These five
agreements also provide for additional payments upon attainment of
research and product development milestones and royalty payments
based on sales of any products that result form use of the Company’s
technology or proprietary database information. The Company also has
an agreement with a pharmaceutical company for the development of a
database for predicting drug toxicity. Under that agreement, the
Company may license the database and other products developed
pursuant to the agreement to third party customers. In addition, the
Company has agreements with a major pharmaceutical company, a life
science technology company and a biotechnology company for
bioinformatics software, database development, and data integration.
Under these agreements, the Company receives annual software
license fees and development fees. Finally, the Company also has
additional four agreements with major pharmaceutical companies in
which the Company receives fees for gene expression and genomic
analysis of samples for the profiling of drugs both at the preclinical and
clinical trial stages of development.

Biotech Bay Office:
Gene Logic
Bioinformatics Systems Division
2001 Center Street, Suite 600
Berkeley, CA 94704
Phone: [phone]
Fax: [phone]

Key Management:
Michael J. Brennan, M.D., Ph.D.,CEO
Mark D. Gessler, President and COO
Greg G. Lennon, Ph.D., SVP Research & Development & CSO
Daniel R. Passeri, J.D., SVP Technology & Program Management
Eric M. Eastman, Ph.D., VP Technology Management
Victor M. Markowitz, D.Sc., VP, Bioinformatics Systems Division
Alan L. Lichtenstein, VP, Human Resources & Administration
Douglas Dolginow, M.D.Senior Vice President, Pharmacogenomics
Philip L. Rohrer, Jr., Chief Financial Officer
David S. Murray,Senior Vice President, Marketing and Sales

würde mich freuen wenn Biotechexperten wie Lupo1 etc. sich rege beteilligen.


mfg

[coltseavers]

werden die in Deutschland gehandelt ??

[sarma]

Hallo
Mich würde mal interessieren,woher Du Lupo1 hast?
Sarma

[Meier M]

Servus coltseavers u. sarma,

@coltseavers

WKN 910845

@sarma

hatte mal ein paar Beiträge im board gelesen.


tja, war nicht unser tag!

21,75$


mfg

[Meier M]

servus mtiggy

hast du das von affx gelesen! wow da könnten wir einigen auftrieb bekommen!

mfg

[tjatja]

Guten Morgen @all

der zusammenhang mit affx müßte eigentlich ein volltreffer sein! mein einstiegskurs v.
22$ wird sich bezahlt machen!

Article for Gene Logic Inc (NASDAQ NM:GLGC)
6:01 AM



most recent headlines
next article:






Gene Logic Signs UCB Pharma to GeneExpress(TM) Subscription And Announces Expansion of Custom
Discovery Partnership


MONDAY, OCTOBER 02, 2000 6:01 AM
- PRNewswire

GAITHERSBURG, Md. and CAMBRIDGE, Mass., Oct 2, 2000 /PRNewswire via COMTEX/ -- Gene Logic Inc. (Nasdaq:GLGC), a
leading provider of genomic information, and UCB Research, a division of UCB Pharma, a global pharmaceutical company with
headquarters in Brussels, Belgium, announced today that UCB has subscribed to a segment of Gene Logic`s GeneExpress(TM)
Suite of databases for use in UCB`s drug discovery and development programs and they have expanded their current custom
discovery partnership regarding development of a custom gene expression database for new drug discovery focused on allergy.
Financial terms of the multi-year subscription and the expanded custom partnership were not disclosed.

Under the terms of the GeneExpress subscription, UCB will gain access to a subset of the GeneExpress Suite, specifically the Atlas
DataSuite. The GeneExpress Atlas DataSuite is an interactive information suite containing gene expression profiles of a broad survey
of normal human tissue, enabling researchers to quickly access normal gene expression levels across a broad selection of relevant
human organs and tissues. UCB Pharma becomes the first major pharmaceutical company to subscribe to the Atlas DataSuite,
which Gene Logic launched in August 2000. The agreement provides for broad deployment of the Atlas DataSuite and its related
software tools across UCB Pharma`s global pharmaceutical research and development infrastructure.

Also under terms of the agreement, Gene Logic will construct a separate, custom database incorporating UCB`s proprietary genomic
data which will allow UCB researchers to readily cross-reference this proprietary data with the nonproprietary data available in the
GeneExpress Atlas DataSuite.

Under the expanded custom partnership regarding allergic disease gene discovery, Gene Logic will use its patented READS(TM)
technology and Affymetrix Inc.`s (Nasdaq:AFFX) GeneChip(R) technology to identify genes that are differentially regulated in mast
cells and other cells central to allergic disease. Gene Logic will continue to apply this multiple platform approach for purposes of
providing UCB novel drug targets. In addition, the partnership affords Gene Logic the opportunity to gain rights to certain data
generated from these studies for eventual inclusion into the GeneExpress Suite.

"We look forward to another productive year of target discovery research with our collaborators at Gene Logic," said Dr. Tom Beck,
UCB Global Director of R&D. "The tools offered by Gene Logic together with our proprietary mast cell technology, have permitted a
significant leap in our understanding of this key allergic cell. The next stage of this research promises to take us to a higher level of
defining disease mechanisms in asthma and other allergic disorders in which the mast cell plays a central pathological role."

"We are thrilled that UCB Pharma, a current custom partner of ours, has not only expanded its existing agreement, but, more
importantly, has chosen to subscribe to one of our GeneExpress DataSuites," said David S. Murray, Senior Vice President,
Marketing and Sales of Gene Logic. "This multifaceted agreement incorporating both a partnership and subscription component is
one of the cornerstones of our vision of Gene Logic`s business model going forward. Clearly, we have established ourselves as an
invaluable resource for the entire research group at UCB."

UCB Pharma Overview

UCB Pharma is a global leader in the research, manufacture and marketing of innovative therapeutics for allergy, respiratory and
central nervous system disorders. These products include Zyrtec(R) (cetirizine HCl), a leading antihistamine, and Keppra(R)
(levetiracetam), a novel anti-epileptic drug marketed in the U.S. and Europe by UCB. UCB Group is a world scale company based in
Brussels, Belgium, which is active in the pharma, chemical and film sectors. UCB`s research activities seek to promote health, well
being and quality of life. The company currently employs over 9,000 people worldwide, of which 700 are dedicated to advancing UCB`s
pharmaceutical research and development efforts. UCB Research, Inc., based in Cambridge, Ma., is a division of UCB Pharma.

For more information, visit the company`s Web site at http://www.ucb- group.com.

Gene Logic Overview

Gene Logic Inc. is a leading provider of genomic information, enabling the discovery and development of pharmaceutical,
biotechnology, health care, and life science products through the systematic and industrialized application of genomics and
bioinformatics. Gene Logic has built and is commercializing the world`s most comprehensive survey of gene expression in human and
animal tissues. Gene expression, which is the degree to which genes in a cell are switched on or off, or regulated, is information
critical to understanding the functions of genes. Gene Logic markets two types of gene expression database products to the global
pharmaceutical, biotechnology, health care and life science industries: its custom databases and related software products and the
GeneExpress Suite of databases. The GeneExpress Suite can be used to discover and validate novel drug targets, develop and
prioritize therapeutic compounds and facilitate clinical trials and patient management. Today, thirteen companies use Gene Logic`s
various gene expression products for drug discovery, predictive toxicology, diagnostic applications, and the identification of genes for
agricultural applications.

For more information about Gene Logic, visit the company`s Web site at http://www.genelogic.com or telephone toll-free on
1-800-GENELOGIC.

All statements in this press release that are not historical are considered forward-looking statements within the meaning of Section
21E of the Securities Exchange Act of 1934, as amended, including statements regarding Gene Logic`s "expectations," "beliefs,"
"goals," "hopes," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to
differ materially for Gene Logic from those projected, including, but not limited to, risks and uncertainties relating to technological
approaches, product development, production, market acceptance, cost and pricing of Gene Logic products, utility of genomic
information in drug discovery and development, dependence on collaborative partners, sole source suppliers, competition, customer
renewals and terminations, intellectual property of Gene Logic and others, and patent protection and litigation. These and other risk
factors are discussed in Gene Logic`s Annual Report on Form 10-K for the year ended December 31, 1999 and Gene Logic`s other
SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods.

SOURCE Gene Logic Inc.

[Meier M]

alleine die kunden von GLGC sind diesen preis wert!


mfg